CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination With Niraparib in the Treatment of Recurrent Ovarian Cancer
CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's...